China Diabetes Cardiovascular Initiative

Diabetes Mellitus Clinical Trial

— CDCV  

Official title:

China Diabetes Cardiovascular Initiative

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05037058
• Other study ID #: CDCV2021
• Status: Not yet recruiting
• Start date: September 1, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: August 2021
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: Yongchen Hao, Ph. D
• Phone: +86(10)64456549
• Email: haoyongchen123[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9600
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients hospitalized with acute coronary syndrome and diabetes.

2. Aged at least 18 years. Exclusion Criteria: None

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Diabetes Mellitus

Intervention

Other:
• Quality improvement activities
Quality improvement activities

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of STEMI patients receiving reperfusion therapy by PCI		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of NSTE-ACS patients receiving risk stratification at admission		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients prescribed dual antiplatelet medications at discharge		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients with indications prescribed a beta-blocker at discharge		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients prescribed a statin at discharge		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients with indications prescribed an ACE-I or ARB at discharge		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients that receiving an LDL-C assessment		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients with evaluation for LV systolic function by echocardiography		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of smoking patients that receiving smoking cessation advice/counseling		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients receiving fasting glucose test at least twice		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients receiving HbA1C test		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients with body height and weight measured and documented		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients receiving guidance on individualized dietary		Duration of hospital stay, an expected average of 1 week
Primary	Proportion of patients receiving guidance on individualized physical activity		Duration of hospital stay, an expected average of 1 week